| scholarly article | Q13442814 |
| P50 | author | Mazen Hassanain | Q50997920 |
| P2093 | author name string | Nathaniel Bouganim | |
| Petr Kavan | |||
| Ayat Salman | |||
| Peter Metrakos | |||
| Prosanto Chaudhury | |||
| P2860 | cites work | The adaptive response of the reticuloendothelial system to major liver resection in humans. | Q50736035 |
| Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study | Q57823590 | ||
| Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy | Q71656886 | ||
| Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes | Q79303814 | ||
| Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases | Q82053797 | ||
| Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases | Q82294696 | ||
| Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential | Q83180826 | ||
| Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial | Q24647888 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey | Q30004207 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Trends in long-term survival following liver resection for hepatic colorectal metastases | Q34523502 | ||
| Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival | Q34551117 | ||
| Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases | Q34557044 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection | Q35598081 | ||
| Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy | Q35607802 | ||
| Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases | Q36464103 | ||
| A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. | Q36549218 | ||
| Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases | Q36742173 | ||
| Gastrointestinal perforation due to bevacizumab in colorectal cancer | Q36759132 | ||
| Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. | Q37303627 | ||
| Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history | Q43990247 | ||
| Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. | Q44486167 | ||
| Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology t | Q44592606 | ||
| Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. | Q44785271 | ||
| Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). | Q45023757 | ||
| Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases | Q46835869 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| bevacizumab | Q413299 | ||
| chemotherapy | Q974135 | ||
| liver metastasis | Q18967325 | ||
| P304 | page(s) | 37-42 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Hepato Pancreato Biliary | Q15756742 |
| P1476 | title | Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis | |
| P478 | volume | 12 |
| Q37308725 | Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). |
| Q41525440 | Emergency open incarcerated hernia repair with a biological mesh in a patient with colorectal liver metastasis receiving chemotherapy and bevacizumab uncomplicated wound healing. |
| Q36609383 | Incidence and predictive factors of clinically relevant bile leakage in the modern era of liver resections |
| Q36343047 | Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents |
| Q35826810 | Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis |
| Q45094736 | Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases |
| Q36063355 | Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases |
| Q49127329 | Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases |
| Q38019380 | Therapeutic strategies for hepatic metastasis of colorectal cancer: overview |
| Q37561000 | Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer |
| Q36072776 | Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases |
| Q37407384 | Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases |
Search more.